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Abstract
Background: Prevalence of multiple health risk behaviors is growing, and obesity and smoking are costly. Weight
gain associated with quitting smoking is common and can interfere with quit success. Efficacy of adding weight
management to tobacco cessation treatment has been tested with women in group sessions over an extended
period of time, but has never been tested in real-world settings with men and women seeking help to quit. This
paper describes the Best Quit study which tests the effectiveness of delivering tobacco and weight control
interventions via existing quitline infrastructures.
Methods: Eligible and consenting smokers (n = 2550) who call a telephone quitline will be randomized to one
of three groups; the standard quitline or standard quitline plus a weight management program added either
simultaneously or sequentially to the tobacco program. The study aims to test: 1) the effectiveness of the combined
intervention on smoking cessation and weight, 2) the cost-effectiveness of the combined intervention on cessation
and weight and 3) theoretically pre-specified mediators of treatment effects on cessation: reduced weight concerns,
increased outcome expectancies about quitting and improved self-efficacy about quitting without weight gain.
Baseline, 6 month and 12 month data will be analyzed using multivariate statistical analyses and groups will be
compared on treatment adherence, quit rates and change in weight among abstinent participants. To determine
if the association between group assignment and primary outcomes (30-day abstinence and change in weight at
6 months) is moderated by pre-determined baseline and process measures, interaction terms will be included in
the regression models and their significance assessed.
Discussion: This study will generate information to inform whether adding weight management to a tobacco
cessation intervention delivered by phone, mail and web for smokers seeking help to quit will help or harm quit
rates and whether a simultaneous or sequential approach is better at increasing abstinence and reducing weight
gain post quit. If proven effective, the combined intervention could be disseminated across the U.S. through
quitlines and could encourage additional smokers who have not sought cessation treatment for fear of gaining
weight to make quit attempts.
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Background
Comorbid smoking and obesity are a public health
problem
Obesity and smoking account for over three quarters of
a million deaths per year in the U.S. [1–3] and about
92 % of smokers have at least one additional health risk
behavior [4–8]. More than nine million adults are both
obese and smoke [9], markedly increasing their mortality
risk [2, 3]. Although effective smoking cessation treat-
ments are available [10–13], weight gain following cessa-
tion is common [14–18]. Modest weight gain of about
8-10 lb is the norm, but some smokers gain more than
20 lb after quitting. There is evidence that obese smokers
and smokers concerned about post-cessation weight gain
may experience greater than average weight gain after
quitting and cessation related weight gain can increase the
risk for weight related health conditions [16, 19–24]. A
systematic review of interventions focused on preventing
post cessation weight gain confirmed prior research find-
ings that 80–90 % of smokers gain weight after quitting;
that only 10–20 % gain more than 10 kg and that the
weight gain is generally permanent unless changes in life-
style are adopted [25]. The authors concluded that there
are very few interventions that entirely prevent post cessa-
tion weight gain, but there is evidence of modest effects
for reducing the amount of weight gained.
Efficacy of combined weight and cessation interventions
has been established and can help smokers quit while
minimizing weight gain
A systematic review of randomized controlled trials that
compared combined behavioral smoking and weight
management treatment with smoking treatment alone
found that the combined interventions produced a sig-
nificant improvement in cessation and reduced weight
gain over tobacco treatment alone in the short term with
a similar but non-significant trend at 6 or 12 months
[26]. In this review by Spring and colleagues, 779 articles
were identified from searching PubMed, Ovid MEDLINE,
CINAHL, EMBASE, PsycINFO and Cochrane Central
Register of Controlled Trials, and 10 trials met eligibility
criteria and were included in the meta-analysis. Of the
2233 adults who participated (2079 females and 154
males), those who received both smoking and weight
treatment showed increased abstinence [odds ratio (OR)
= 1.29, 95 % confidence interval (CI) = 1.01, 1.64] and
reduced weight gain (g = -0.30, 95 % CI = -0.57, -0.02) in
the short term (<3 months) compared with patients who
received smoking treatment alone. Differences in abstin-
ence (OR = 1.23, 95 % CI = 0.85, 1.79) and weight control
(g = -0.17, 95 % CI = -0.42, 0.07) were in the same direc-
tion but no longer significant in the long term (>6 months)
[26]. One of these studies, also conducted by Dr. Spring
and colleagues, showed that a sequential treatment
approach which provided cessation treatment first, followed
by weight management treatment, reduced weight gain to a
greater extent than simultaneous treatment and cessation
treatment alone and showed a non-significant trend for
better cessation rates [27]. Similarly, Copeland and col-
leagues tested a sequential approach to weight management
following two weeks of cessation treatment and found that
individually tailored weight management resulted in higher
cessation rates than group treatment. Groups did not differ
in weight gain and the study did not have a tobacco cessa-
tion only treatment group [28]. According to the most
recent Cochrane review, some smoking cessation interven-
tions that included personalized weight management sup-
port or very low calorie diets may limit post cessation
weight gain without harming abstinence rates, but only in
the short term [29]. The review also reported that exercise
interventions can reduce weight gain without undermining
quit attempts over the long term and that bupropion and
fluoxetine were better at suppressing weight gain than NRT
but only while using the medications [29].
Most of the successful smoking cessation interventions
designed to prevent cessation-related weight gain focused
on calorie restriction or meal replacement, behavioral
counseling on weight control, some form of exercise and/
or cessation medications [29–35]. In addition to dietary
and physical activity interventions, a weight acceptance
approach has been tested in three trials [32, 36, 37]. The
rationale behind this line of research stems from research
findings that excessive concerns about weight gain can
interfere with successful quitting. Thus the intervention
aims to address maladaptive beliefs about weight, encou-
rage acceptance of moderate weight gain and to focus on
tobacco cessation. In the original weight concerns trial,
Perkins found that adding an intervention aimed at
addressing and reducing maladaptive weight concerns
simultaneously with smoking cessation treatment resulted
in a significant improvement in cessation, as compared to
cessation treatment alone. Weight gain among those who
quit smoking also differed across groups. At 6 and
12 months, weight gain was significantly lower for the
weight concerns group [2.9 ± 2.6 kg and 2.5 ± 4.2 kg] com-
pared with the weight control group [4.1 ± 4.8 kg and 5.4
± 3.3 kg] and cessation only treatment [6.4 ± 3.5 kg and
7.7 ± 4.7 kg] [36]. The second weight concerns study
involved a 2x2 randomized trial offering standard cessa-
tion alone vs. the weight concerns intervention crossed
with placebo or bupropion. Results showed that among
women offered bupropion to help with cessation, those
randomized to the weight concerns intervention had
significantly greater levels of abstinence at 6 months than
did standard smoking cessation counseling combined with
bupropion or placebo and a non-significant increase in
weight gain at 6 months with no effect on weight at
12 months. A third trial of the weight concerns
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intervention tested the effectiveness of this weight accep-
tance approach in a population-based setting of a national
tobacco quitline among 2000 male and female smokers
seeking help to quit smoking. Results were published after
the three systematic reviews and showed that at 6 months
the intervention had a significant weight suppressive effect
without impacting cessation [37].
These results highlight the difference between “weight
concerns” interventions which strive to increase smoking
cessation and are not consistently associated with weight
suppression after quitting, and “weight loss/weight man-
agement” interventions involving diet or targeted beha-
vioral weight loss approaches which do reduce weight
gain. Overall, the aggregated findings in these reviews
provide no evidence that combining smoking treatment
and behavioral weight control undermines either absti-
nence or weight control and some evidence of benefit
for both. Although systematic reviews have established
that combining weight management with tobacco cessa-
tion treatments are a safe and moderately successful
approach for reducing weight gain and improving cessa-
tion outcomes in the short term, most trials used inten-
sive, in-person, group interventions and very few included
males [25, 26, 29, 38]. Such intensive interventions are
unlikely to be adopted at a population level, and if they
were, would be unproven for half of the population. A
sound knowledge base is needed to inform treatment
decisions about best practices for the growing population
with multiple health risk behaviors. Since the prior efficacy
study conducted by Spring and colleagues suggests that
sequential weight control treatment can suppress cessa-
tion related weight gain [27], there is a need to determine
whether the prior finding is replicable in a population
based setting and for both short and long-term tobacco
and weight outcomes.
Quitlines provide an ideal setting in which to integrate
tobacco cessation with recommended behavioral treat-
ments for other health risk behaviors. Quitlines are freely
available in all 50 states and the U.S. territories, have the
potential to reach large populations of smokers and have
proven to be effective and cost-effective [10–13, 39].
Quitlines offer a range of services including multiple
counseling calls with cessation specialists, mailed support
materials and access to modest regimens of nicotine patch
or nicotine gum (NRT) [13, 39, 40]. Given the risk of both
continued smoking and weight gain, it is worthwhile to
test successful but intensive combined interventions
adapted for population delivery via a telephone quitline.
This paper describes the design, methods, adapted inter-
ventions and analytic approach for such a clinical trial.
The rationale for our study is to replicate and scale the
prior efficacy trial described by Spring that tested the
simultaneous or sequential addition of weight control
treatment compared with tobacco cessation treatment
alone [27]. If a combined phone and web based weight
control program added to a standard phone/web based
cessation treatment had benefits for cessation and weight
control, such a program would have substantial reach and
public health benefit.
Methods
Study design, setting and population
The Best Quit Study is a 3-arm randomized controlled
trial in which quitline callers are assigned to one of three
treatment groups: standard quitline (cessation treatment
alone), quitline plus a weight control treatment added
simultaneously, or quitline plus a weight control treat-
ment added sequentially to the cessation program. The
study will be conducted at Alere Wellbeing, which ope-
rates telephone quitlines as well as a weight manage-
ment program delivered by phone, mail and web. The
tobacco quitline and the weight control program are
based on social cognitive theory [41], utilize similar coun-
seling call structures and are supported by comprehensive
computer-based tracking and support systems. The com-
bined treatments aim to facilitate use of tobacco and
weight control treatments to increase the proportion of
smokers who achieve medium (6 months) and long-term
(1 year) tobacco abstinence and to minimize weight gain.
The population will include 2550 smokers recruited
from Alere Wellbeing’s commercial quitlines (employer
groups and health care organizations) and participating
state quitlines. Alere Wellbeing operates quitlines for 28
states and more than 800 geographically diverse employer
groups and health plans and serves more than 20,000
smokers per month. Study participants will be recruited
from individuals who call in to a participating quitline for
cessation treatment. Individuals are eligible to participate
if they are 18 years or older, smoke 10 or more cigarettes
per day (cpd) and are ready to quit smoking in the next
30 days. Exclusion criteria include enrolling in the web-
only program, being pregnant or planning to become
pregnant within three months, having diabetes, recent or
planned weight loss surgery, BMI < 18.5, having an eating
disorder, inability to understand English, having no access
to the internet or email, being unavailable in the next two
weeks, and unwilling to participate in ten counseling calls.
As this study takes place in a real-world, phone-based
setting, the entire recruitment and enrollment process,
including informed consent, will be handled over the
phone. Interested individuals who agree to hear more
about the study will be transferred to a team of trained
research coaches, who will describe the study in detail,
obtain informed verbal consent and collect baseline data.
Eligible and consenting participants are immediately
randomized by a computer generated program into one of
three study arms: Standard Care (tobacco only), Simulta-
neous (tobacco and weight), and Sequential (tobacco
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followed by weight) and enrolled into the study to begin
intervention. A copy of the consent form (See Additional
file 1) will be mailed to study participants after enrollment,
along with other study materials.
Process data will be collected using Alere Wellbeing’s
automated call tracking system and stored in a secure sys-
tem. Outcome data will be collected 6 and 12 months after
randomization (see Fig. 1: Study Design). We will collect
outcome data via surveys administered first by email, then
phone, then mailed, for all participants randomized into
the study and who do not withdraw consent for follow-up.
Strategies to promote follow-up completion include in-
centives for completing surveys, $2 pre-incentives sent
with mailed surveys, and an additional incentive for com-
pleting the 12-month email survey within 72 h. Telephone
outcome assessors, who will receive specialized training
on the study, will be blinded to the intervention assign-
ment. All outcome survey data will be collected via a
secure link to DatStat, a survey collection database.
Interventions
The intervention for all three groups includes 10 coach-
ing calls, mailed materials, and access to one or more
web-based programs plus unlimited participant initiated
calls for help quitting for up to 12 months from enroll-
ment in the quitline. Standard Care participants receive
5 quit smoking calls followed by 5 calls focused on tips
for healthy living (contact control calls). Participants in
the simultaneous arm receive 5 calls focused on quitting
smoking integrated with the weight management con-
tent followed by 5 calls focused on tips for healthy living.
Participants in the sequential arm receive 5 quit smoking
calls first followed by 5 weight management calls (see
Table 1: Call sequence for: Quit Smoking (Q), Weight
Management (W), and Contact Control (CC) groups).
The smoking cessation intervention
All participants will receive standard cessation treatment
services as dictated by their coverage plan, individual
needs, and preferences. This includes the Quit For Life®
and state quitline programs, which combines individua-
lized telephone counseling, mailed written materials, and
an interactive online program (Web Coach®) designed to
complement the phone-based treatment sessions. Partici-
pants receive up to 5 counseling calls (1 reactive; 4 pro-
active), each designed to provide practical expert support
to help participants develop problem-solving and coping
skills, secure social support, and design a plan for success-
ful cessation and long-term abstinence. As is standard in
the quitline programs, participants may be eligible to
receive over-the-counter (OTC) and prescription cessation
medications, including Nicotine Replacement Therapy
(NRT) in the form of patch, gum or lozenge, and vareni-
cline. Because eligibility for cessation medications varies
by state or commercial contract, medications may not be
provided uniformly across all study participants.
The behavioral weight control intervention
The weight management program (Weight Talk®) is a
phone and web based weight management-lifestyle pro-
gram. The program integrates behavioral, psychological
and biological science with highly skilled coaching. Con-
tent of the intervention comes from physical activity and
dietary behavior change interventions proven to be
efficacious [42–45]. For this study, Weight Talk® will act
as the brief, adapted version of the weight control pro-
gram used in the prior efficacy study [27]. All coaching
calls, the mailed materials and the interactive web
encourage and support goal setting and regular self-
monitoring of weight, choice of foods, calorie reduction,
physical activity, and stress reduction. The recommenda-
tions that form the basis of Weight Talk® include the
NIH Clinical Guidelines on Identification, Evaluation
and Treatment of Overweight and Obesity in Adults as
well as the NIH-developed “Dietary Approaches to Stop
Hypertension” (DASH) protocol [46]. The DASH diet
has been proven to not only help reduce body weight
Fig. 1 Study design
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Table 1 Call sequence for Quit Smoking (Q), Weight Management (W), and Contact Control (CC) calls
Week: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Standard
care




















































































but also to lower blood pressure, blood lipids and dia-
betes risk factors independent of weight control [46, 47].
The physical activity component of the program is based
on the U.S. Public Health Service Guidelines (http://
www.ahrq.gov/professionals/clinicians-providers/guide
lines-recommendations/tobacco/index.html). The activity
component encourages more moving and less sitting with
an overall goal of walking 3 to 4 times per week and grad-
ually increasing the time and speed up to > =60 min per
session. The stress reduction component helps individuals
identify and control stressful situations, find and practice
coping skills and monitor progress. The stress reduction
module uses evidence based behavioral treatments to help
participants reduce the harmful effects of stress that are
common in dieters as well as in smokers [48]. The treat-
ment goal is to prevent stress from inhibiting successful
behavior change. For this trial, Weight Talk® will be
adapted to focus on prevention of weight gain rather than
weight loss for people trying to quit smoking. A registered
dietician will work with participants to set a calorie goal of
approximately 300 cal fewer than their current diet. Redu-
cing calories by this amount is likely to offset the potential
weight gain associated with a reduction in metabolism
associated with withdrawal of nicotine. Weight will be
assessed during each counseling call and calorie adjust-
ments can be tailored to each individual.
Healthy lifestyle contact control calls
The standard of care quitline program consists of 5
counseling calls. Because adding Weight Talk® to the
smoking cessation treatment in the sequential treatment
results in a total of 10 calls, five neutral (contact control)
calls need to be added to the standard 5-call quitline
group and the simultaneous weight group to equalize
the number of contacts. Equality in call number reduces
the potential for inequality in subject burden, differential
dropout rates and differential response rates to the 6
and 12 month surveys. The ‘contact control’ calls will be
delivered by trained coaching staff and the duration is
approximately that of a standard care call. The contact
control calls will not include weight or tobacco related
content. We therefore chose the following ‘neutral’
topics, the content of which is unlikely to affect smoking
or a person’s weight:
1. Sunscreen Protection (the coach discusses risks of
excessive sun exposure, and behavioral steps a
person can take to protect themselves and family).
2. Prevent the Flu/Hand Washing (the coach discusses
steps a person can take to reduce their risk of
contracting influenza).
3. Pedestrian Safety (the coach provides education
about pedestrian safety and tips to increase safety as
a pedestrian or driver).
4. Disaster Preparedness (the coach provides a
background on the importance of disaster
preparedness and provides recommendations on
steps a person can take).
5. Energy Savings/Home Efficiency (the coach
discusses implications of inefficient energy
consumption in homes and steps to reduce costs).
Counselor qualifications and training
Separate teams of equally competent counselors will de-
liver the tobacco or the weight based treatment. Tobacco
cessation specialists (quit coaches) will be college educated
with at least two years of counseling experience, consistent
with prior quitline intervention trials [37, 40, 49]. Weight
coaches will also be college educated and have at least
two years of counseling experience. Registered dieti-
cians who deliver the second call in the Weight Talk®
program will be board certified and experienced. All
counselors will have completed at least 100 h of train-
ing in the treatment approach as well as ongoing call
monitoring and supervision.
Data safety and monitoring board
The DSMB will consist of at least three independent
members who, collectively, have experience in the con-
duct and monitoring of randomized clinical trials. A
quorum will require at least two members. Upon con-
vening, the DSMB will vote on who will serve as the
chair. The DSMB membership is restricted to individuals
free of apparent significant conflicts of interest. The
source of these conflicts may be financial, scientific or
regulatory in nature. Thus, study investigators are not
members of the DSMB. DSMB members may not own
stock greater than value allowed by institutional policy,
in or have consulting agreements with a tobacco indus-
try sponsor. The DSMB members will disclose conflicts
of interest to fellow members. Any DSMB member who
has or develops a significant conflict of interest should
resign from the DSMB. DSMB membership is for the
duration of the clinical trial. If any members leave the
DSMB during the course of the trial, the PI will promptly
appoint their replacement. The expected frequency of the
DSMB meetings will be twice annually. Ad hoc meetings
may be scheduled as needed. The DSMB will hold its first
meeting prior to the study launch and will hold its second
meeting three months after study launch. The study team
will prepare open and closed reports for DSMB members
to review on a quarterly basis. The open report will include
the study design, protocol amendments, status of dropouts,
and compliance. The closed report will be blinded to the PI
and will include demographics by study arm, analyses of
primary and secondary efficacy endpoints, and severe ad-
verse events (SAEs). The purpose of the DSMB meetings is
to review the conduct of the trial to date and assess safety
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and efficacy of the study intervention. The DSMB will re-
view severe adverse events and determine whether the
study should be prematurely discontinued.
Discontinuing intervention
We will discontinue weight treatment for participants
who report during the course of treatment a BMI < 18.5,
pregnancy, or other condition that would have made them
ineligible for the study at enrollment, however they may
continue with the standard tobacco cessation program.
There are no restrictions on concomitant care or interven-
tions for the participants during course of the trial.
Intervention fidelity
To monitor adherence to the cessation and weight inter-
vention protocols (and the healthy living protocols), four
raters will assess a 10 % random sample of participants’
audio-taped calls. Treatment fidelity will be assessed
using a Call Quality Monitoring Tool (CMT) for the
study. Treatment fidelity for Quit Coaches includes evalu-
ation of implementing correct procedures for assessing and
dosing of NRT and adherence to treatment protocols ac-
cording to the PHS Guidelines [10] and recommended the-
ory based topics advised for each call. A similarly rigorous
CMT will be used to code recorded calls delivered by the
Weight Coaches to assess their adherence to content spe-
cific to the weight control intervention, including their abil-
ity to utilize Social Cognitive Theory (SCT) to identify and
help participants’ overcome their barriers to change [41].
Analysis of treatment fidelity will be performed quarterly.
If fidelity for any sampling falls below 80 %, the pool of
coaches will receive booster trainings on study content.
Measures
Data for analyses will come from information collected
when a person registers with the quitline, baseline data
collected by a quit coach, 6 and 12 month phone or on-
line follow-up data collected by a survey team and
Alere’s tracking information on number and duration of
counseling calls completed.
Primary outcome measures will be self-reported 30-
day point prevalent abstinence and self-reported change
in weight at 6 months.
Secondary outcome measures include 7-day point
prevalence and continuous abstinence at 6 and 12 months,
and reduction in amount smoked in continuing smokers.
Other data will include descriptive and process data for
analyses of mediators and moderators of intervention
effects and cost data.
Survey content will be derived from standardized
validated measures used to assess tobacco history, weight
variables and outcomes, and from prior research findings
and theoretical underpinnings of efficacious clinical trials
[27, 33, 34, 37, 40, 50]. Most of the following measures
will be assessed at baseline and/or 6 & 12 months and
used to describe participants and evaluate outcomes.
Demographics: age, gender, race, ethnicity, education,
height, weight, and other general demographics.
Chronic Disease: assessed by asking participants if they
have ever been diagnosed with diabetes, heart disease,
asthma, or a lung disease.
Depressive symptoms: measured with the PHQ-2, a 2
item screening measure for depressive symptoms that
has demonstrated strong criterion and construct validity.
The scale uses a 4-point response option to assess
frequency of dysphoria and anhedonia. Sensitivity of the
PHQ-2 has been reported at 84 %, with 72 % specificity
for a cut score of 3 [51].
Perceived stress: measured with the 4-item Perceived
Stress Scale (PSS), to assess the degree to which respon-
dents find their lives to be stressful. The PSS has been
shown to be a valid and reliable measure with alpha
reliability coefficients from .84 to .86 [52]. PSS scores
have been shown to be related to smoking relapse [53].
Smoking/quit attempt history: lifetime and current
smoking, cigarettes smoked per day, history of quit
attempts, prior use of nicotine replacement and other ces-
sation treatments, and exposure to other household users.
Nicotine dependence: Fagerström Test of Nicotine
Dependence (FTND) [54], which is the most commonly
used measure for assessing nicotine dependence and is
predictive of abstinence [55].
Self-efficacy for quitting: using the question “How
confident are you that you could quit smoking for
good?” which has been used to assess confidence and
predict smoking cessation [56].
Self-efficacy for preventing weight gain: using the
weight concerns questionnaire [57].
Weight concerns: assessed with 2 questions: “On a
scale of 0–100, how concerned are you about gaining
weight after quitting?” and “On a scale of 0–100, how
concerned would you be if quitting smoking caused you
to permanently gain 10 lb?”
Physical and sedentary activities – using standard
measures to assess days per week (and minutes/day) in
moderate/vigorous activity.
Dietary behaviors: assessed by asking about the num-
ber of fruits and vegetables consumed in a typical day
and the number of days per week participants include at
least 5 fruits and vegetables.
Treatment utilization: assessed via automated records
of use of Alere Wellbeing counseling calls, the website,
pharmacotherapy, and other services provided by the
tobacco quitline. Utilization of treatments not provided
through the study will also be assessed in the follow-up
survey.
Smoking outcomes: assessed at 6 and 12 months to
characterize 7- and 30-day point prevalence reports of
Bush et al. BMC Public Health  (2016) 16:615 Page 7 of 12
nonsmoking and continuous abstinence using definitions
recently recommended by the Society for Research on
Nicotine and Tobacco (SRNT) [58].
Reduction in amount smoked: asked for those who
continue to smoke at 6 months or 12 months and calcu-
lated as the difference in cigarettes smoked per day at
baseline and follow-up.
Post-cessation weight gain: the difference between self-
reported weight at registration/baseline and follow-up.
Outcome expectations for success at smoking cessation
and weight control: single-item 10-point scales to rate
participants’ expectations about the degree to which
treatment would (a) help them quit smoking, (b) minimize
weight gain, and (c) be effective overall. In the original
efficacy trial [27], one-month test–retest reliabilities for
these single-item scales ranged as follows: .36–.71 for
outcome expectations about quitting smoking, .42–.59 for
expectations about minimizing weight gain, and .34–.74
for expectations about the program overall, with ratings
showing increased reliability later in treatment. Data from
the original efficacy trial indicates that adding weight
management increased outcome expectations for absti-
nence [27]. We will assess whether groups are similar at
baseline on these measures and will evaluate these
measures in mediator analyses.
Sample size and power analysis
Alere’s historical 30+ day self-reported abstinence rate at
6 months based on an intent to treat protocol (all eli-
gible for survey are included) is 29.6 % for employer and
health plan clients and 20 % for state quitlines. The
lower quit rates for state quitlines likely reflects socio-
economic differences (eg more uninsured smokers and
lower education and income). Survey response rates are
also lower in state quitlines. By enrolling 850 parti-
cipants per treatment group, we expect to have 80 %
power to detect a difference in the abstinence rate
between the standard quitline control condition and the
combined treatment groups of 5.7 % or greater (ie an
odds ratio of 1.30) using a Fisher’s exact test. Similarly,
we can detect a difference between standard care and
either of the combined treatment groups of 6.5 % (OR =
1.34) or greater. The detectable odds ratio may be
slightly smaller when testing for treatment effectiveness
using logistic regressions controlling for baseline BMI,
gender, age, and nicotine dependence. We estimate that
at 12 months the abstinence rates will decrease by 3 %
in each group, resulting in 80 % power to detect a
change of 5.5 % (ie an odds ratio of 1.31). Effect sizes
from other studies have shown that an increase in quit
rates of 2.5 % or greater are clinically significant. For
example, the quit rate without advice from a physician is
7.9 % versus 10.2 % with physician advice [10]. Our
detectable effect size is also comparable to the effects of
many different treatments that are widely applied in
clinical practice. For example, without help, individuals
have an estimated 10.8 % abstinence rate versus 13.1 %
with proactive telephone counseling, 13.9 % with group
counseling, and 16.8 % with individual counseling [10].
Since behavioral counseling is recommended, this dem-
onstrates that increases on the order of 2.3 to 6.0 % are
clinically relevant. Data from Alere’s standard services
experience and a prior study were used to calculate the
standard deviation of calculated post-treatment absti-
nence rates [37].
Statistical analysis plan
Aim 1. The primary cessation and weight change out-
comes will be assessed at 6 months and the secondary
outcomes at 12 months. We hypothesize that combined
treatments will be more effective than standard treat-
ment and that sequential treatment will be more effec-
tive than simultaneous treatment for increasing quit
rates or reducing weight gain, without harming the other
outcome. The primary analysis approach for testing the
effectiveness of the combined treatments on cessation
will be logistic regression with an indicator for the main
effect of treatment and an interaction term to account
for the difference in treatment effectiveness of the two
treatments. The regression equation will also include
baseline characteristics that are predictive of abstinence
(age, gender, etc.) and an indicator of whether the par-
ticipant is qualified for receiving NRT through their
State quitline plan. Analyses of cessation will be con-
ducted three ways: 1) using multiply imputed values for
missing cessation status; 2) on the set of responders to
follow-up (ie, those for whom we know the cessation
outcome), 3) assuming that non-responders (lost to
follow-up) have relapsed. We will also conduct sensiti-
vity analyses for missing cessation results by reanalyzing
the data with different assumed probabilities of relapse.
The primary analysis approach for testing the effective-
ness of the combined treatments on weight will be linear
regression. The regressions will include an indicator for
the main effect of treatment, an interaction term to ac-
count for differences in treatment effectiveness, current
cessation status and the interaction of treatment group
and current cessation status as covariates, thus allowing
estimates of weight gain for all participants and (as sec-
ondary analyses) for quitters and smokers. A regression
approach that is robust to heterogeneity in variance will
be used. We will address missing values using multiple
imputation as well as conducting sensitivity analyses
with different assumed amounts of weight gain for non-
responders to determine how extreme such weight gains
(or differential weight gains among non-responders in
different groups) would need to be to invalidate statisti-
cally significant results.
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For all of the aims, preliminary analyses will include
summary statistics (mean, standard deviation, skewness,
kurtosis, range), cross tabulations of baseline variables
and outcomes for each group, correlations among vari-
ables, and plots of outcome variables versus time. Stand-
ard regression diagnostics will be performed including
examination for heteroscedasticity, outliers, observations
with large leverage, observations with large influence,
and normality of residuals (where appropriate). Outcome
variables may be transformed to improve the normality
of residuals. Plots (such as residuals versus covariates
and residuals versus fitted values) will be generated to
examine the model fit. The Benjamini-Hochberg proce-
dure will be used to adjust the p-value for multiple com-
parisons separately for primary and secondary measures.
The general analysis approach for the secondary mea-
sures will be repeated measures logistic, ordinal, Poisson,
or linear regression depending on the type of outcome
measure [59].
Aim 2 involves analyses to test the cost-effectiveness
of the combined interventions over standard care for
cessation and for weight. We hypothesize that combined
treatments are more cost effective than standard treat-
ment and sequential more cost-effective than simulta-
neous for cessation and weight. With respect to cost per
quitter, cost-effectiveness analyses will be conducted to
quantify: 1) the cost per quitter for the standard and
combined treatment, 2) the incremental cost per quitter
of the combined treatment (relative to the standard
cessation program), and 3) the relative cost-effectiveness
of the combined treatment versus other treatments in
the literature. Treatment costs will be calculated on the
basis of Alere’s employer and state reimbursements for
the smoking cessation program (which may include
NRT treatment) and weight management treatment. In
addition, we will calculate the cost per quality adjusted
life year gained using the approach described by Javitz
[60]. With respect to weight gain, cost-effectiveness
analysis will be conducted to calculate the cost per pound
not gained (ie, the additional cost of the weight manage-
ment treatment divided by the difference between the
weight gain in the standard and combined treatment
group) and this cost will be compared to medical costs
associated with weight gain from the literature [61–63]
and to the cost per pound lost from commercially avai-
lable weight reduction programs (since presumably indi-
viduals in the standard quitline group could use such
programs to lose weight or prevent weight gain).
Aim 3 includes analyses to evaluate theoretically pre-
specified mediators of treatment effects on cessation.
To test whether changes attributable to the weight
management program mediate the cessation rate, we will
examine changes in weight concerns, weight, outcome
expectancies on quitting, and self-efficacy in quitting
without weight gain. Mediation implies a causal hypo-
thesis whereby an independent variable (ie, the weight
management program) causes a mediator (eg, reduced
weight concerns) that causes a change in a dependent
variable (ie, cessation) [64]. We will follow four steps to
test mediation effects [65, 66]. For example, to assess
whether reduced weight concerns mediates cessation, we
must: (1) demonstrate significantly different cessation
outcomes for weight management and comparison
groups, (2) demonstrate differences in weight concerns
by condition, (3) establish that reduced weight concerns
is significantly related to cessation rate, and (4) show
that the effect of a weight management intervention on
cessation rate is significantly less after controlling for
change in weight concerns. We will further test whether
changes in outcomes expectancies of treatment on quit-
ting, self-efficacy in quitting without weight gain, phy-
sical activity and diet (eg fruits and vegetables) mediate
the effect of the weight management program on weight
gain. Regression analyses will be conducted to examine
the moderating effects on cessation and weight gain of
baseline characteristics of BMI, age, gender, weight
concerns, nicotine dependence, outcome expectancies
and self-efficacy in quitting. Moderators will be included
in the regression analyses as mean-centered covariates
and as interaction terms with the combined treatment
group indicator.
Exploratory analyses will also assess mediators of
weight gain and whether baseline BMI, weight concerns,
self-efficacy, outcome expectancies, nicotine depen-
dence, use of medications, age and gender moderate the
effectiveness of the different interventions for cessation
and weight outcomes.
All analyses will be conducted using SAS or STATA
software.
Discussion
This paper describes the Best Quit Study which com-
pares tobacco cessation treatment alone or combined
tobacco and weight control treatment for improving the
dual outcomes of abstinence and weight gain prevention
and tests whether a simultaneous or sequential approach
is more effective and cost effective than standard to-
bacco cessation treatment alone. The trial attempts to
replicate a prior efficacy trial by translating and adapting
the interventions for delivery within a population based
setting of a quitline. Potential limitations include differ-
ences between the implemented effectiveness trial and
the original efficacy trial and the use of self-reported
outcomes. We have translated the original, in-person,
group based intervention to accommodate the real-world
phone based treatments offered through the quitline. We
did not offer meal replacement food, but our Weight Talk®
intervention includes a mailed education packet with an
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activity tracker and charts to monitor weight and physical
activity. As such, the resultant intervention has the poten-
tial for broad reach and widespread adoption. The use of
self-reported, non-validated outcome measures, remain a
potential limitation. Using blinded non-study survey
professionals for delivering the phone based follow-up
surveys have been shown to reduce bias in reporting
smoking status and weight [58, 67, 68].
Conclusions
The trial was successfully implemented and was accept-
able to quitline participants. Our experience replicating
the original efficacy trial and adapting the interventions
for delivery through existing national quitlines was
presented at the European Society on Nicotine and To-
bacco Research in Santiago De Compestella, Spain in
September 2014 [69]. The study results will be reported
according the CONSORT statement for cluster random-
ized trials [70].
Public health impact
Given the national epidemic of obesity and the costs of
smoking among overweight adults, population-based
smoking cessation treatments are needed that increase
abstinence and prevent weight gain. This study could
identify a strategy for translating efficacious smoking
and weight control interventions from research to prac-
tice (ie through standard quitline operations), thereby
increasing the reach and impact of combined treatment
in the population. Results will address the question of
whether a simultaneous or sequential intervention on
multiple behaviors (smoking cessation, diet and exercise)
is helpful or harmful to cessation or weight outcomes. If
either a simultaneous or sequential combined interven-
tion improves cessation and limits weight gain, dissem-
ination of such interventions could have a significant
scientific, clinical and public health impact by encour-
aging more quit attempts in the population, reducing
relapse, improving long-term health outcomes, and re-
ducing weight-related comorbidities, long-term medical
costs, and costs associated with post-study weight reduc-
tion programs. This study will be an important replica-
tion test of prior efficacy studies in that it uses a more
acceptable setting (quitlines) that contains existing
tobacco and weight control services.
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